China Medical System (867.HK) Maintains ESG Recognition with S&P Global Sustainability Yearbook and MSCI Rating
SHENZHEN, CHINA, July 16, 2024 — China Medical System Holdings Limited (“CMS” or the “Group”) has again been recognized for its strong performance and dedication to sustainable development. CMS has been included in the 2024 Sustainability Yearbook (China Edition) by S&P Global, a leading global corporate sustainability assessment organization. CMS also maintained its “AA” rating in the latest MSCI (Morgan Stanley Capital International) ESG Rating Report.
Re-inclusion in S&P Global’s Sustainability Yearbook (China Edition)
The 2024 Sustainability Yearbook (China Edition) from S&P Global has been published. With a CSA score of 51, exceeding 91% of its global industry peers, CMS stood out among over 1,700 evaluated Chinese companies to be included in the China Yearbook. This makes CMS one of only five selected companies in the pharmaceutical industry.
Maintaining “AA” Rating in MSCI ESG Rating
In July, MSCI released its latest ESG rating report for CMS. The Group has retained its “AA” rating, placing it at the leading level in the industry globally.
CMS is dedicated to its ESG vision of “becoming a world-leading sustainable pharmaceutical enterprise,” continuously promoting the deep integration of sustainability concepts into its development strategy. The Group has established an ESG strategy that addresses various operational dimensions, aligning with the Group’s mission and vision, and the expectations of stakeholders. Through a robust governance structure, CMS continuously strengthens its ESG management and practices to achieve its ESG strategic goals.
The Group’s high appraisal from these two internationally recognized organizations reflects the ongoing recognition of the value and effectiveness of CMS’s sustainable development efforts and practices. Looking ahead, CMS will continue to strengthen its ESG governance and overall performance in corporate operations, social contributions, and environmental protection, working collaboratively with all stakeholders to promote sustainable development and contribute to a green, healthy, and prosperous future for all.
About CMS
CMS is a platform company that bridges pharmaceutical innovation and commercialization with strong product lifecycle management capabilities. The company is committed to providing competitive products and services that address unmet medical needs.
CMS focuses on global first-in-class (FIC) and best-in-class (BIC) innovative products. The company efficiently promotes the clinical research, development, and commercialization of innovative products, transforming scientific research into clinical practices that benefit patients.
CMS is deeply involved in several specialty therapeutic fields and has developed proven commercialization capabilities, extensive networks, and expert resources. These factors have resulted in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand its business boundaries. While strengthening the competitiveness of its cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields while enhancing scale and efficiency. Concurrently, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further supporting the Group’s sustainable and healthy development.
CMS Disclaimer and Forward-Looking Statements
This press release, prepared by CMS, does not constitute any offer or invitation to purchase or subscribe for any securities and should not be used as the basis for, or relied upon in connection with, any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data that it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness, and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Disclaimer Statement of MSCI
The use by China Medical System Holdings Ltd. of any MSCI ESG Research LLC or its affiliates (“MSCI”) data, and the use of MSCI logos, trademarks, service marks, or index names herein, do not constitute a sponsorship, endorsement, recommendation, or promotion of China Medical System Holdings Ltd. by MSCI. MSCI services and data are the property of MSCI or its information providers, and are provided ‘as-is’ and without warranty. MSCI names and logos are trademarks or service marks of MSCI.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email:
Website:
Source: China Medical System Holdings Ltd.